EGFR Kinase Compounds for C797S Resistance and Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors, such as Gefitinib, Erlotinib, Afatinib, and Osimertinib, face challenges with drug resistance due to secondary mutations like T790M and C797S, leading to limited efficacy in treating non-small cell lung cancer, with no effective single inhibitor available for EGFR C797S mutation.
Innovation Solution
Development of compounds that inhibit EGFR kinase or induce its degradation through the ubiquitin-proteasome pathway, utilizing specific chemical structures to target and degrade EGFR, potentially overcoming drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR inhibitors (Gefitinib, Erlotinib, Afatinib, Osimertinib) are used to treat non-small cell lung cancer, then tumor cell proliferation is inhibited and apoptosis is promoted, but drug resistance develops due to secondary mutations (T790M, C797S)
Solution Approach 1:
The patent changes the mechanism of action parameter from reversible inhibition to covalent binding, and further to degradation induction, to overcome resistance. Osimertinib uses reversible inhibition but fails against C797S mutation; the new compounds use covalent binding to C797S mutant and induce degradation, fundamentally changing how the drug interacts with the target to maintain effectiveness.
Solution Approach 2:
The patent introduces a new intermediary mechanism - the ubiquitin-proteasome system - to achieve degradation of EGFR. Instead of directly inhibiting kinase activity, the compounds induce ubiquitination of EGFR, which then undergoes proteasomal degradation. This intermediary pathway bypasses the resistance caused by mutations that affect direct kinase inhibition.
2Reliability
If Afatinib is used as an irreversible EGFR inhibitor, then it overcomes some drug resistance, but it lacks selectivity to wild-type EGFR and causes great toxicity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target the C797S mutation site exclusively. The compounds contain a specific substituent pattern (R1, R2, R3, R4, R5, R6 definitions in the patent) that provides selective binding to the mutant form while sparing wild-type EGFR, thereby achieving local specificity at the molecular level.
Solution Approach 2:
The patent creates compounds with multi-functionality that can both covalently bind to C797S mutant EGFR and induce its degradation through the ubiquitin-proteasome pathway. This dual functionality allows a single compound to address both the resistance issue and the selectivity issue, unlike Afatinib which only provides irreversible inhibition without degradation capability or selectivity.
3Reliability
If Osimertinib is used to treat EGFR T790M mutation, then drug resistance is overcome, but patients develop resistance after 9-14 months due to EGFR C797S mutation
Solution Approach 1:
The patent inverts the approach by not trying to inhibit the C797S mutant kinase activity directly, but instead targeting the mutation site for covalent binding followed by degradation. Rather than competing with the mutant's altered active site for inhibition, the compounds exploit the cysteine residue at position 797 for covalent attachment, then trigger degradation, effectively working 'the other way round' from traditional inhibition strategies.
Solution Approach 2:
The patent introduces dynamics by inducing degradation of the EGFR protein rather than maintaining a static inhibited state. The ubiquitin-proteasome pathway dynamically removes the mutant EGFR from the system, preventing accumulation and reducing the risk of further resistance development, unlike static inhibition which can be overcome by mutation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit EGFR kinase activity and induce its degradation, offering a potential solution to drug resistance in non-small cell lung cancer, particularly for mutations like C797S, enhancing treatment efficacy.
Implementation Method 1
inducing degradation of EGFR through the intracellular ubiquitin-proteasome pathway
Data Source
AI summary
Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a preparation and use of the above inhibitor.